M&A Buzz In Korea: CJ HealthCare On the Block
Executive Summary
CJ Group plans to sell its healthcare affiliate, in what could potentially emerge as the first major M&A deal involving a South Korean pharma firm in recent years. Although the company has not ruled out the option of an initial public offering as an alternative, the sale plan possibly reflects the changing dynamics in the Korean pharma industry.
You may also be interested in...
Can Daewoong’s P-CAB Unsettle Competition?
Daewoong Pharmaceutical has successfully completed a Phase III clinical trial of next generation gastroesophageal reflux disease (GERD) drug candidate in South Korea, but strong competition awaits from approved P-CAB drugs of CJ Healthcare and Takeda.
Kolmar Korea Eyes Pharma Expansion Via CJ HealthCare Acquisition
The acquisition of mid-size South Korean pharma firm CJ HealthCare is set to boost Kolmar Korea's pharma business, enabling the cosmetics and pharma company to transform into a larger and more integrated healthcare firm.
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.